Comprehensive genomic and immunohistochemical profiles and outcomes of immunotherapy in patients with recurrent or advanced cervical cancer

Purpose This study aimed to investigate genomic and immunohistochemical (IHC) profiles and immunotherapy outcomes in patients with cervical cancer. Methods Patients with recurrent cervical cancer who underwent tumor next-generation sequencing (NGS) with the TruSight Oncology 500 panel at Yonsei Cancer Center between June 2019 and February 2022, were identified. Patients who received treatment with checkpoint inhibitors during the same period were also identified. Clinical information, including histology, stage, human papillomavirus (HPV) genotype, IHCs profile, and therapy outcome, was reviewed. Results We identified 115 patients treated for recurrent cervical cancer, including 74 patients who underwent tumor NGS. Most of these 74 patients were initially diagnosed with advanced stage (63.6%) and had squamous cell histology (52.7%), and high-risk HPV (76.9%). Based on IHC analysis, the programmed death-ligand 1 combined positive score (PD-L1 CPS) was higher in patients with squamous cell carcinoma (SCC) than in those with adeno or mucinous types (P=0.020). HER2 receptor expression of 2+ and 3+ were identified in 5 and 1 patients, respectively, and significantly varied based on histology (p=0.002). Among the 74 patients, single nucleotide variants (SNVs) and copy number variations (CNVs) were identified in 60 (81.1%) and 13 patients (17.6%), respectively. The most common SNVs were PIK3CA, TP53, STK11, FAT1, and FBXW7 mutations. Mutations in PIK3CA, with two hotspot mutations, were frequently observed in patients with SCC histology, whereas mutations in TP53 were frequently observed in patients with non-SCC histology. Additionally, variations in FAT1 were exclusively identified in patients with SCC histology. Mutations in homologous recombination repair-associated genes were identified in 18 patients (24.3%). The most frequent CNV alteration was CCNE1 amplification. Moreover, among the 36 patients who underwent NGS and received immunotherapy, the tumor mutational burden and microsatellite instability were significantly correlated with immunotherapy duration. During this timeframe, 73 patients received pembrolizumab monotherapy, among whom a small portion showed a durable response. Conclusion Comprehensive genomic and IHC profiling may help identify potential candidates for targeted immunotherapy in patients with cervical cancer.

[1]  Li Li,et al.  Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Xiao-hua Wu,et al.  Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature , 2022, Frontiers in Oncology.

[3]  B. Monk,et al.  Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Ávila,et al.  Human papillomavirus-independent cervical cancer , 2021, International Journal of Gynecological Cancer.

[5]  Shigeki Tanishima,et al.  Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors , 2021, Scientific Reports.

[6]  Joon Jeong,et al.  PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection , 2021, Scientific Reports.

[7]  Ariel Esteban Bardach,et al.  Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis , 2021, PloS one.

[8]  A. Italiano,et al.  Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study , 2021, Gynecologic Oncology.

[9]  A. Leroux,et al.  A NGS-based Blood Test For the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization , 2021, Clinical Cancer Research.

[10]  T. Buhl,et al.  Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches , 2021, Cancers.

[11]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[12]  M. Khasraw,et al.  Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? , 2020, Clinical Cancer Research.

[13]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[14]  J. Machiels,et al.  Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Luca Mazzarella,et al.  Tumor mutational burden quantification from targeted gene panels: major advancements and challenges , 2019, Journal of Immunotherapy for Cancer.

[16]  Jason D. Wright,et al.  Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. , 2019, Obstetrics and gynecology.

[17]  B. Monk,et al.  Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial , 2019, Gynecologic oncology.

[18]  A. Italiano,et al.  Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Isabelle Salmon,et al.  Methods of measurement for tumor mutational burden in tumor tissue. , 2018, Translational lung cancer research.

[20]  H. Rugo,et al.  Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[22]  Steven J. M. Jones,et al.  Integrated genomic and molecular characterization of cervical cancer , 2017, Nature.

[23]  W. Park,et al.  HER2 as a novel therapeutic target for cervical cancer , 2015, Oncotarget.

[24]  Trevor J Pugh,et al.  Landscape of genomic alterations in cervical carcinomas , 2013, Nature.

[25]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[26]  B. Monk,et al.  Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[28]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[29]  K. Tewari,et al.  Changing paradigms in the systemic treatment of advanced cervical cancer. , 2016, American journal of obstetrics and gynecology.